MedPath

Phase II study of Pemetrexed and Bevacizumab in Performance status 2 patients with advanced non-squamous non-small cell lung cancer.

Phase 2
Recruiting
Conditions
non-squamous non-small cell lung cancer
Registration Number
JPRN-UMIN000008124
Lead Sponsor
iigata Lung Cancer Treatment Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
25
Inclusion Criteria

Not provided

Exclusion Criteria

1) History of hemoptysis 2) High risk of bleeding or thrombus events 3) History of anticoagulant within 10 days before enrollment 4) Active radiation pneumonitis or esophagitis 5) Uncontrollable hypertension 6) Symptomatic brain metastasis 7) Scheduled operation 8) Severe complications 9) Problematic infection 10) History of active double cancer 11) No intention to birth control 12) Unstable psychic disorder 13) History of treatment drug 14) Decision of ineligibility by a physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PFS
Secondary Outcome Measures
NameTimeMethod
RR,DCR,OS,TTF,QOL,safety
© Copyright 2025. All Rights Reserved by MedPath